430 related articles for article (PubMed ID: 19029957)
1. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer C; Mazzone M; Jonckx B; Carmeliet P
Nat Rev Cancer; 2008 Dec; 8(12):942-56. PubMed ID: 19029957
[TBL] [Abstract][Full Text] [Related]
2. The function of vascular endothelial growth factor.
Nieves BJ; D'Amore PA; Bryan BA
Biofactors; 2009; 35(4):332-7. PubMed ID: 19415738
[TBL] [Abstract][Full Text] [Related]
3. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.
Luttun A; Tjwa M; Moons L; Wu Y; Angelillo-Scherrer A; Liao F; Nagy JA; Hooper A; Priller J; De Klerck B; Compernolle V; Daci E; Bohlen P; Dewerchin M; Herbert JM; Fava R; Matthys P; Carmeliet G; Collen D; Dvorak HF; Hicklin DJ; Carmeliet P
Nat Med; 2002 Aug; 8(8):831-40. PubMed ID: 12091877
[TBL] [Abstract][Full Text] [Related]
4. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders.
Luttun A; Tjwa M; Carmeliet P
Ann N Y Acad Sci; 2002 Dec; 979():80-93. PubMed ID: 12543719
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.
Shibuya M
BMB Rep; 2008 Apr; 41(4):278-86. PubMed ID: 18452647
[TBL] [Abstract][Full Text] [Related]
6. [anti-angiogenic drugs].
Sato S
Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):184-5. PubMed ID: 22891390
[No Abstract] [Full Text] [Related]
7. Regulators of angiogenesis as targets for anti-angiogenic tumor therapy.
Breier G; Heidenreich R; Gaumann A; Groot M; Licht A; Nicolaus A; Schmitz J; Reichmann E; Plate KH; Vajkoczy P
Ann Hematol; 2002; 81 Suppl 2():S71-2. PubMed ID: 12611084
[No Abstract] [Full Text] [Related]
8. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii S; Lyden D; Benezra R; Hattori K; Heissig B
Nat Rev Cancer; 2002 Nov; 2(11):826-35. PubMed ID: 12415253
[No Abstract] [Full Text] [Related]
9. The VEGF pathway in cancer and disease: responses, resistance, and the path forward.
Kieran MW; Kalluri R; Cho YJ
Cold Spring Harb Perspect Med; 2012 Dec; 2(12):a006593. PubMed ID: 23209176
[TBL] [Abstract][Full Text] [Related]
10. Blockage of VEGF-induced angiogenesis by preventing VEGF secretion.
Björndahl M; Cao R; Eriksson A; Cao Y
Circ Res; 2004 Jun; 94(11):1443-50. PubMed ID: 15192038
[TBL] [Abstract][Full Text] [Related]
11. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
Tarallo V; De Falco S
Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
[TBL] [Abstract][Full Text] [Related]
12. VEGF function in vascular pathogenesis.
Ng YS; Krilleke D; Shima DT
Exp Cell Res; 2006 Mar; 312(5):527-37. PubMed ID: 16330026
[TBL] [Abstract][Full Text] [Related]
13. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
Taylor AP; Osorio L; Craig R; Raleigh JA; Ying Z; Goldenberg DM; Blumenthal RD
Clin Cancer Res; 2002 Apr; 8(4):1213-22. PubMed ID: 11948135
[TBL] [Abstract][Full Text] [Related]
15. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.
Autiero M; Waltenberger J; Communi D; Kranz A; Moons L; Lambrechts D; Kroll J; Plaisance S; De Mol M; Bono F; Kliche S; Fellbrich G; Ballmer-Hofer K; Maglione D; Mayr-Beyrle U; Dewerchin M; Dombrowski S; Stanimirovic D; Van Hummelen P; Dehio C; Hicklin DJ; Persico G; Herbert JM; Communi D; Shibuya M; Collen D; Conway EM; Carmeliet P
Nat Med; 2003 Jul; 9(7):936-43. PubMed ID: 12796773
[TBL] [Abstract][Full Text] [Related]
16. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?
Luttun A; Autiero M; Tjwa M; Carmeliet P
Biochim Biophys Acta; 2004 Mar; 1654(1):79-94. PubMed ID: 14984769
[TBL] [Abstract][Full Text] [Related]
17. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
18. A new weapon for attacking tumor blood vessels.
Semenza GL
N Engl J Med; 2008 May; 358(19):2066-7. PubMed ID: 18463385
[No Abstract] [Full Text] [Related]
19. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide.
Lacal PM; Morea V; Ruffini F; Orecchia A; Dorio AS; Failla CM; Soro S; Tentori L; Zambruno G; Graziani G; Tramontano A; D'Atri S
Eur J Cancer; 2008 Sep; 44(13):1914-21. PubMed ID: 18682321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
